Remove 2004 Remove Consumption Remove Epilepsy Remove Patients
article thumbnail

Election Brings Big Wins for Cannabis Legalization

Canna Care Docs

Details: Allows the possession of up to one ounce of cannabis and no more than five grams of concentrate Permits individuals to possess up to six cannabis plants in their homes Public consumption prohibited In addition to local taxes and 16% excise tax, state sales tax of 5.6% Medicinal cannabis was already approved in Montana in 2004.

article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

Because of the very rapid progression of ALS in the majority of patients, understanding how cannabis could help in the alleviation of symptoms is incredibly important for ALS sufferers. Both upper and lower motor neurons suffer severe damage in ALS patients. As few as 10% of ALS patients live longer than 10 years after being diagnosed.

Strains 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Does Cannabis Legalization Look Like in the UK?

Veriheal

In 2004, cannabis was reclassified as a class C drug but was reinstated to Class B in 2008 following Prime Minister Gordon Brown’s decision to go against the advice offered up by the Advisory Council on the Misuse of Drugs. . Despite that, the following punishments have been handed out for cannabis-related consumption or possession.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.